Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Non-Current Debt (2016 - 2022)

Historic Non-Current Debt for Aptevo Therapeutics (APVO) over the last 7 years, with Q4 2022 value amounting to $1.5 million.

  • Aptevo Therapeutics' Non-Current Debt fell 6072.3% to $1.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.5 million, marking a year-over-year decrease of 6072.3%. This contributed to the annual value of $1.5 million for FY2022, which is 6072.3% down from last year.
  • As of Q4 2022, Aptevo Therapeutics' Non-Current Debt stood at $1.5 million, which was down 6072.3% from $1.9 million recorded in Q3 2022.
  • Over the past 5 years, Aptevo Therapeutics' Non-Current Debt peaked at $25.2 million during Q3 2020, and registered a low of $1.5 million during Q4 2022.
  • Moreover, its 5-year median value for Non-Current Debt was $9.3 million (2018), whereas its average is $11.1 million.
  • As far as peak fluctuations go, Aptevo Therapeutics' Non-Current Debt soared by 3892.67% in 2019, and later plummeted by 8407.87% in 2021.
  • Aptevo Therapeutics' Non-Current Debt (Quarter) stood at $19.3 million in 2018, then rose by 1.45% to $19.6 million in 2019, then rose by 2.54% to $20.1 million in 2020, then tumbled by 81.51% to $3.7 million in 2021, then crashed by 60.72% to $1.5 million in 2022.
  • Its Non-Current Debt stands at $1.5 million for Q4 2022, versus $1.9 million for Q3 2022 and $2.4 million for Q2 2022.